Trial Profile
Phase III study of gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer with EGFR mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Dec 2019 Results of final Overall survival analyses in 5-year follow-up were published in the Annals of Oncology
- 25 Sep 2019 Results of a post-hoc 5-year follow-up analysis, published in the Annals of Oncology
- 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.